Experienced neuroscience drug developers and biotech operators

Peter Lansbury is a CeraLink co-founder and the company’s chief scientist. He developed an interest in ceramide metabolism during his nine years as Chief Scientific Officer of Lysosomal Therapeutics, which was sold to Bial in 2021. Before Lysosomal Therapeutics, Peter was Chief Scientific Officer at Link Medicine, which he co-founded with Adam Rosenberg. Before moving to biotech, Peter spent more than 20 years in academia, first in the Department of Chemistry at MIT and then at Harvard Medical School, where he was promoted to full professor of neurology in 2004. His academic work focused on elucidating the mechanism of protein aggregation in neurodegenerative diseases, including Alzheimer’s disease, prion disease, and Parkinson’s disease. He has served on numerous scientific advisory boards in both biotech and the nonprofit sector.

Peter received his AB in chemistry from Princeton University and his PhD in organic chemistry from Harvard University under the direction of Nobel laureate E. J. Corey. He completed his postdoctoral fellowship at the Rockefeller University, working with the late Tom Kaiser.

Nuno Mendonça, MD, is a neurologist and drug development executive with more than 15 years of experience in clinical research and industry, focused on neurology and rare diseases. He was Chief Medical Officer and Executive Committee member at AC Immune, and before that Chief Medical Officer and Senior Vice President at Bial. In both roles he led clinical development, medical affairs, and drug safety for neurodegenerative and orphan disease pipelines. At Novartis Gene Therapies, he played a key role in the European approval and launch of Zolgensma for spinal muscular atrophy. At AbbVie, he led clinical strategy for anti-tau antibody programs in Alzheimer’s disease and progressive supranuclear palsy. Nuno holds an MD from the University of Coimbra and trained in clinical research at Harvard Medical School.

Adam Rosenberg is a CeraLink co-founder, investor, and board member. He brings more than 20 years of industry experience in founding and building innovative biotech companies, with a particular focus on neuroscience companies. Adam is currently CEO of RyCarma Therapeutics and serves as chair and independent director on multiple boards. Most recently, Adam served as CEO and director of Aliada Therapeutics (acquired by AbbVie), Athenen Therapeutics (merged with Eliem/Climb Bio), and Sionna Therapeutics. Previously, he was CEO and director of Rodin Therapeutics (acquired by Alkermes), Link Medicine, and Teleos Therapeutics. He holds a JD from the University of Virginia School of Law and a bachelor’s degree from Whittier College.

Jonathan Alspaugh is a CeraLink co-founder, investor, and board member. He is an experienced biotechnology executive with more than 15 years advising and operating in the biopharmaceutical industry. His background ranges from advising global pharmaceutical companies to founding, funding, and leading early-stage biotech and healthcare ventures. Most recently, Jonathan was President and Chief Strategy Officer at RyCarma Therapeutics, a clinical-stage biotech company developing small molecule, ryanodine receptor allosteric modulators for rare skeletal muscle diseases. Prior to that, he was President and CFO at Aeglea BioTherapeutics, a public biotech company developing engineered human enzyme therapeutics to treat ultra-rare inborn error of metabolism diseases.

Prior to his operating roles, Jonathan spent more than 10 years in investment banking at Evercore and Barclays where he advised on M&A transactions and financings for biotech and healthcare companies. Jonathan holds an MBA from the MIT Sloan School of Management, an SM from the Harvard-MIT Division of Health Sciences and Technology, and BSE and MSE degrees in nuclear engineering and radiological sciences from the University of Michigan.

Tim Andruszkiewicz brings more than 15 years of experience in biopharma transactions and operations across business development, M&A, financing, alliance management, and corporate strategy.

Tim leads corporate development at RyCarma Therapeutics and previously led corporate development at Aeglea BioTherapeutics through its merger with Spyre Therapeutics. Prior to Aeglea, Tim was a key member of the corporate development team that helped build Horizon Therapeutics into a leading rare disease company acquired by Amgen. Earlier in his career, Tim worked as a healthcare investment banker, advising on strategic transactions and financings across the sector.

Tim holds a BBA from the University of Notre Dame’s Mendoza College of Business.

Craig Justman is a CeraLink co-founder and currently leads the company’s biomarker development efforts. He has more than 20 years of biotech experience developing therapeutics for Parkinson’s disease at Link Medicine, Lysosomal Therapeutics, and Bial. His work has primarily focused on alpha-synuclein aggregation and toxicity, sphingolipid biology, and the development and deployment of pharmacodynamic biomarkers. He holds a PhD from Harvard University’s Department of Chemistry and Chemical Biology and completed his postdoctoral work at Harvard Medical School.